Most of the attempts to treat AD have focused on these pathogenic mechanisms, including an increase in cholinergic neurotransmission with cholinesterase inhibitors (donepezil, rivastigmine and galantamine), NMDA receptor (NMDAR) antagonist (memantine) and, recently, with monoclonal antibodies directed against Aβ [3]. The gene discussed is BCHE; the disease is Alzheimer disease.